end-stage heart failure
Conditions
Interventions
Test group:Recombinant human brain natriuretic peptide, dosage 0.01 ug/kg/min, continuous micro-pump application for 3 days
Sponsors
Shanghai Tenth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Age range: 18 - 85 years old, gender not restricted; 2. Patients diagnosed with end-stage heart failure ; 3. Have received the most optimized evidence-based drug treatment for at least 4 weeks (unless there are contraindications or intolerance); 4. Have signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Cardiogenic shock or hemodynamic instability; 2. Systolic blood pressure < 90 mmHg; 3. Acute myocardial infarction or unstable angina pectoris within 4 weeks; 4. Planned to undergo heart transplantation or mechanical circulatory support during the trial; 5. Severe valvular disease requiring surgical treatment; 6. Estimated glomerular filtration rate < 15 mL/min/1.73m² or renal replacement therapy; 7. Severe liver dysfunction (Child-Pugh C grade); 8. Malignant tumor or life expectancy < 12 months; 9. Pregnant or lactating women; 10. Allergic to rhBNP or any of its components; 11. Patients with low cardiac filling pressure; 12. Participated in other clinical trials within the past 30 days;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| New York Heart Association,NYHA; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life;NT-proBNP;6-minute walk distance;Noninvasive Hemodynamic Monitoring;Renal function; | — |
Countries
China
Contacts
Public ContactDachun Xu
Shanghai Tenth People's Hospital
Outcome results
None listed